Anatomy of female reproductive system
Yes with introduction and definition
labeled diagram female reproductive system internal organs uterus ovaries uterine tubes vagina
female reproductive anatomy
female reproductive system anatomy uterus ovaries uterine tubes vagina anatomy
https://www.ncbi.nlm.nih.gov/sites/books/NBK554601

| Organ | Main arterial supply | Venous drainage |
|---|---|---|
| Ovary | Ovarian artery from abdominal aorta | Right ovarian vein to inferior vena cava; left ovarian vein to left renal vein |
| Uterus | Uterine artery, branch of internal iliac artery | Uterine venous plexus to internal iliac veins |
| Vagina | Vaginal artery and branches of uterine artery | Vaginal venous plexus to internal iliac veins |
| Vulva | Internal pudendal artery | Internal pudendal veins |
Uterine cancer diagnostic evaluations with purpose
NCI endometrial cancer diagnosis tests biopsy transvaginal ultrasound staging
endometrial cancer diagnosis
https://www.cancer.gov/types/uterine/hp/endometrial-treatmen…
| Evaluation | Purpose |
|---|---|
| History taking | Identifies symptoms and risk factors. Important symptoms include postmenopausal bleeding, irregular heavy bleeding, watery or blood-stained vaginal discharge, and pelvic pain. Risk factors include obesity, diabetes, prolonged estrogen exposure, tamoxifen use, and Lynch syndrome. |
| General and pelvic examination | Evaluates the vulva, vagina, cervix, uterus, and adnexa. It may detect uterine enlargement, a pelvic mass, cervical involvement, vaginal spread, or another source of bleeding. A normal examination does not exclude endometrial cancer. |
| Transvaginal ultrasonography (TVUS) | Uses a vaginal ultrasound probe to examine the uterus and measure endometrial thickness. Its purpose is to assess abnormal bleeding, identify thickened endometrium, polyps, fibroids, or an intrauterine mass, and help decide whether tissue sampling is needed. It supports evaluation but does not confirm cancer. NCI screening guidance |
| Endometrial biopsy or sampling | A thin catheter, commonly a Pipelle device, is passed through the cervix to obtain endometrial tissue. This is the main outpatient test to confirm or exclude malignancy and identify hyperplasia, cancer type, and often tumor grade. A tissue sample is necessary for a definitive diagnosis. NCI diagnostic evaluation |
| Dilation and curettage (D&C) | The cervix is dilated and endometrial tissue is scraped or suctioned. It is used when an office biopsy is inadequate, impossible, or negative despite persistent suspicious bleeding. Its purpose is to obtain a larger tissue sample for histopathology. |
| Hysteroscopy with directed biopsy | A thin telescope is introduced through the cervix to view the uterine cavity directly. It detects focal lesions such as polyps or localized tumors that may be missed by blind biopsy, and allows a targeted biopsy. Berek & Novak’s Gynecology notes that hysteroscopy provides information not obtained by blind endometrial sampling. |
| Histopathological examination | A pathologist examines biopsy or curettage tissue under a microscope. Its purpose is to establish the diagnosis, determine histological type, such as endometrioid, serous, or clear-cell carcinoma, determine tumor grade, and identify features relevant to prognosis and treatment. |
| Cervical cytology (Pap test) | Primarily screens for cervical cancer, not uterine cancer. Its purpose in this context is to detect an abnormal cervix or occasionally reveal abnormal endometrial cells that prompt further endometrial evaluation. It cannot rule out endometrial cancer. |
| MRI of pelvis | Helps assess the local extent of confirmed disease, especially depth of myometrial invasion, cervical stromal involvement, and adjacent pelvic-organ involvement. Its purpose is preoperative staging and surgical planning, not primary confirmation of cancer. |
| CT scan of chest, abdomen, and pelvis | Used especially for high-grade, advanced, or symptomatic disease. It evaluates enlarged lymph nodes, lung, liver, peritoneal, or other distant metastases. |
| PET-CT scan | Not routinely needed for every patient at initial diagnosis. It may be used if recurrent or metastatic disease is suspected, to identify metabolically active lymph-node or distant metastases. |
| Blood tests: CBC, renal and liver function tests | Do not diagnose uterine cancer. Their purpose is to assess anemia caused by bleeding, establish baseline organ function, and determine fitness for imaging, surgery, chemotherapy, or radiotherapy. |
| CA-125 | Not a routine diagnostic test for all endometrial cancers. It may be measured in selected high-risk cases, such as serous carcinoma or suspected extrauterine spread, to support assessment and later monitoring. |
| Molecular testing of tumor tissue | Tests may include mismatch-repair protein immunohistochemistry or microsatellite instability testing, p53 testing, and POLE mutation analysis. Their purpose is to refine prognosis, identify possible Lynch syndrome, classify risk, and guide decisions about adjuvant or systemic therapy. The NCI encourages molecular classification when feasible. NCI treatment reference |
| Surgical staging | After cancer is confirmed, total hysterectomy with removal of both tubes and ovaries is generally performed when appropriate. Sentinel lymph-node biopsy or lymph-node assessment, peritoneal washings in selected cases, and assessment of other tissues determine the true extent of spread and final FIGO stage. |